B
Bernard F. Cole
Researcher at Dartmouth College
Publications - 130
Citations - 13933
Bernard F. Cole is an academic researcher from Dartmouth College. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 57, co-authored 128 publications receiving 13250 citations. Previous affiliations of Bernard F. Cole include University of Vermont & Roger Williams Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized trial of aspirin to prevent colorectal adenomas
John A. Baron,Bernard F. Cole,Robert S. Sandler,Robert W. Haile,Dennis J. Ahnen,Dennis J. Ahnen,Robert S. Bresalier,Gail McKeown-Eyssen,Robert W. Summers,Richard I. Rothstein,Carol A. Burke,Dale C. Snover,Timothy R. Church,John I. Allen,Michael L. Beach,Gerald J. Beck,John H. Bond,John H. Bond,Tim Byers,E. Robert Greenberg,Jack S. Mandel,Norman E. Marcon,Leila A. Mott,Loretta H. Pearson,Fred Saibil,Rosalind U. van Stolk +25 more
TL;DR: Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel, using generalized linear models to compute risk ratios and 95 percent confidence intervals.
Journal ArticleDOI
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
Viviana Galimberti,Bernard F. Cole,Bernard F. Cole,Stefano Zurrida,Giuseppe Viale,Giuseppe Viale,Alberto Luini,Paolo Veronesi,Paolo Veronesi,Paola Baratella,Camelia Chifu,Manuela Sargenti,Mattia Intra,Oreste Gentilini,Mauro G. Mastropasqua,Giovanni Mazzarol,Samuele Massarut,Jean Rémi Garbay,Janez Zgajnar,Hanne Galatius,Angelo Recalcati,David Littlejohn,Monika Bamert,Marco Colleoni,Karen N. Price,Meredith M. Regan,Aron Goldhirsch,Alan S. Coates,Richard D. Gelber,Umberto Veronesi +29 more
TL;DR: Axillary dissection could be avoided in patients with early breast cancer and limited sentinel-node involvement, thus eliminating complications of axillary surgery with no adverse effect on survival.
Journal ArticleDOI
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Bernard F. Cole,John A. Baron,Robert S. Sandler,Robert W. Haile,Dennis J. Ahnen,Robert S. Bresalier,Gail McKeown-Eyssen,Robert W. Summers,Richard I. Rothstein,Carol A. Burke,Dale C. Snover,Timothy R. Church,John I. Allen,Douglas J. Robertson,Gerald J. Beck,John H. Bond,Tim Byers,Jack S. Mandel,Leila A. Mott,Loretta H. Pearson,Elizabeth L. Barry,Judy R. Rees,Norman E. Marcon,Fred Saibil,Per Magne Ueland,E. Robert Greenberg +25 more
TL;DR: In this paper, the safety and efficacy of folic acid supplements for preventing colorectal adenomas were evaluated in a randomized clinical trial. But, the results showed that folic acids at 1 mg/d did not reduce coloreCTal adnoma risk.
Journal Article
Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. Editorial
Bernard F. Cole,John A. Baron,Robert S. Sandier,Robert W. Haile,Dennis J. Ahnen,Robert S. Bresalier,Gail McKeown-Eyssen,Robert W. Summers,Richard I. Rothstein,Carol A. Burke,Dale C. Snover,Timothy R. Church,John I. Allen,Douglas J. Robertson,Gerald J. Beck,John H. Bond,Tim Byers,Jack S. Mandel,Leila A. Mott,Loretta H. Pearson,Elizabeth L. Barry,Judy R. Rees,Norman E. Marcon,Fred Saibil,Per Magne Ueland,E. Robert Greenberg,Cornelia M. Ulrich,John D. Potter +27 more
TL;DR: Folic acid at 1 mg/d does not reduce colorectal adenoma risk and is associated with higher risks of having 3 or more adenomas and of noncolorectAL cancers.
Journal ArticleDOI
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors Report of the Quality Standards Subcommittee of the American Academy of Neurology
Michael Glantz,Bernard F. Cole,Bernard F. Cole,P. A. Forsyth,Lawrence Recht,Lawrence Recht,Patrick Y. Wen,Patrick Y. Wen,Marc C. Chamberlain,Marc C. Chamberlain,Stuart A. Grossman,Stuart A. Grossman,J. G. Cairncross +12 more
TL;DR: The Quality Standards Subcommittee seeks to develop scientifically sound, clinically relevant practice parameters for the practice of neurology with a focus on anticonvulsants in patients with primary and metastatic brain tumors.